P Prognostic role of PSMA PET IMaging and predictive value for toxicity of personalized DOSimetry in patients with hormone-sensitive de novo metastatic prostate cancer treated in phase III PEACE 6 Poor responders trial : Preliminary results of IM-DOSE PEACE 6 PR study (EANM 2026) - Sep 29, 2026 - Abstract #EP-0886; "Aim/Introduction: The PEACE 6 poor responder (PR) trial is an international, multicenter, open-label, controlled, randomized, phase III study promoted by UNICANCER/ GETUG with the aim to evaluate the efficacy and safety of 177Lu-PSMA-617 when administered on top of the ongoing standard systemic treatment compared to SOC alone in PR patients...Materials and De novo mHSPC patients presenting with a serum PSA level of ≥ 0.2 ng/mL at 6- 8 months after androgen deprivation therapy ADT + ARPI +/-docetaxel, in the absence of evidence of cancer progression are included... These preliminary findings from the first cohort of patients enrolled in the PEACE-6 PR trial and analyzed within the IM-DOS-PEACE 6 PR ancillary study demonstrate positive PSMA PET in all included patients, with the majority presenting with multimetastatic disease despite low PSA levels. Further analysis on the first 50 patients will be performed."
Biomarker • Clinical • Metastases • P3 data • P3 data: top line • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
|
|
D. Deandreis 1; C. Garcia 1; A. Bernard-Tessier 1; A. Tauty 2; N. Charrier 2; C. Guery 3; L. Crouzet 3; A. Devillers 3; P. BONNEFOY 4; P. Cornillon 4; O. Huillard 5; M. Wartski 5; A. Giraudet 6; A. Flechon 6; K. Weyts 7; F. Joly 7; N. Simon-Tillaux 1; C. Leger 8; F. Tantot 8; S. Foulon 9; G. Gravis 2; K. Fizazi 10
|